ReviewHistology and histopathology2026
Advances and challenges in developing expandable human hepatocytes for regenerative medicine.
Review in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Liver transplantation remains the only effective treatment for severe liver disease, but donor shortages pose a serious challenge, underscoring the need for alternative therapeutic strategies. Hepatocyte transplantation has been proposed as a promising alternative; however, the lack of expandable cell sources remains a major obstacle. Considerable efforts have been made to establish culture systems that can preserve both the proliferative capacity and functional properties of hepatocytes. Recent advances in expandable hepatocytes and organoid technologies have shown partial success in repopulating injured mouse livers. However, achieving both sufficient cell numbers and robust repopulation efficiency has remained difficult, preventing clinical translation. Furthermore, when cells are transplanted, the engraftment success and replacement efficiency significantly influence the extent of repopulation. In this review, we first revisit the history of hepatocyte transplantation, then summarize recent progress in hepatocyte expansion technologies, and finally discuss the remaining challenges toward clinical application.
Indexed as
Identifiers
41738563What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.